Arcus Biosciences, Inc. - RCUS STOCK NEWS

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to two new employees. The Compensation Committee approved stock options to purchase 7,400 shares at $17.47 per share (the closing price on December 9, 2024) and restricted stock units for 3,700 shares. These equity awards were granted under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.

Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants approved by its Compensation Committee. The grants include options to purchase 10,000 shares of common stock at an exercise price of $14.56 per share, and restricted stock units to acquire 5,000 shares of common stock. These equity awards were granted to three new employees under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company developing cancer therapies, has announced its participation in two major investor conferences in December 2024. The company will attend the Evercore 7th Annual HealthCONx Conference in Coral Gables, FL on December 3rd, featuring a fireside chat at 7:55 a.m. ET and one-on-one meetings. Additionally, Arcus will participate in the Citi 2024 Global Healthcare Conference in Miami, FL on December 4th for one-on-one meetings only. Live webcasts and replays will be available on the company's website.

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted equity awards to four new employees. The grants include options to purchase 14,100 shares of common stock at an exercise price of $17.85 per share, which was the closing price on November 8, 2024. Additionally, the employees received restricted stock units to acquire 7,050 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.

Arcus Biosciences (NYSE:RCUS) reported promising Q3 2024 results, highlighting significant progress in its cancer therapy pipeline. Key developments include positive data from the Phase 1/1b ARC-20 study of casdatifan, showing a 34% objective response rate in renal cell carcinoma patients. The company announced a new collaboration with AstraZeneca for combination therapy studies. Financial position remains strong with $1.1 billion in cash and equivalents, providing runway into mid-2027. Revenue reached $48 million for Q3 2024, up from $32 million in Q3 2023, though net loss increased to $92 million from $71 million year-over-year.

Arcus Biosciences (NYSE:RCUS) announced positive results from Part 1 of ARC-10 study evaluating domvanalimab plus zimberelimab (DZ) in non-small cell lung cancer patients. The combination demonstrated a 36% reduction in death risk compared to zimberelimab alone, with median overall survival not yet reached versus 24.4 months for zimberelimab. The DZ combination showed improved progression-free survival of 11.5 months versus 6.2 months, and higher objective response rate of 44.7% versus 35%. Treatment-related adverse events leading to discontinuation were lower in the DZ group (10.5%) compared to chemotherapy (23.5%).

Arcus Biosciences (NYSE:RCUS) announced four accepted abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, November 6-10, 2024. The key highlight is a late-breaking poster presenting data from ARC-10, including overall survival results for domvanalimab plus zimberelimab in front-line NSCLC patients. The study evaluates this combination versus zimberelimab or chemotherapy in patients with PD-L1-high locally advanced or metastatic NSCLC.

Additionally, an oral presentation will showcase data from an Investigator Sponsored Trial examining domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma. The company will discuss ARC-10 results during its earnings call on November 6, 2024.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to six new employees. The Compensation Committee approved stock options to purchase 28,600 shares at $17.33 per share (the closing price on October 23, 2024) and restricted stock units for 14,300 shares. These awards were granted under the company's 2020 Inducement Plan, which was approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences presented promising first clinical data for casdatifan, their HIF-2a inhibitor, in treating metastatic kidney cancer. The Phase 1/1b study (ARC-20) showed a 34% objective response rate (2 responses pending confirmation) and 25% confirmed response rate in the 100mg daily dose expansion cohort of 32 patients. The treatment demonstrated an 81% disease control rate with only 19% primary progression. Safety profile was manageable, with Grade 3 treatment-related adverse events at 42%, mainly including anemia (36%) and hypoxia (9%). The company plans to initiate PEAK-1, their first Phase 3 study, in the first half of 2025.